These 12 studies could also be categorized into groups by UDCA dosage, or by UDCA Monotherapy or UDCA combined with other drugs. All 12 studies included end-point results presented as concrete ...
Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose ...
Hosted on MSN2mon
Progress in the management of patients with cholestatic liver disease: Where are we and where are we going?The recommended dose is 13–15 mg/kg/day, with higher doses not showing additional benefits. UDCA works by inhibiting hydrophobic bile acid synthesis, enhancing bicarbonate secretion, and ...
Iqirvo (elafibranor) is also the first new therapy for PBC in more than a decade, getting a green light as a second-line therapy in combination with ursodeoxycholic ... an 80 mg dose of ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...
All five studies assessing UDCA combination therapy showed significant improvements liver function, while two studies also improved steatosis and inflammation. One study of high-dose UDCA showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback